In Vivo Ameliorative Effects of Vitamin E against Hydralazine-Induced Lupus

Loading...
Thumbnail Image
Date
2023
Authors
Githaiga, Fiona Muthoni
Omwenga, George Isanda
Ngugi, Mathew Piero
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ
Abstract
ABSTRACT Objective In this study, we investigated the in vivo ameliorative effects of vitamin E in a hydralazine-induced lupus model, which closely resembles SLE in humans. We aim to shed light on its potential as a therapeutic agent for managing SLE. Methods Forty BALB/c mice were used in this study. Hydralazine hydrochloride was orally administered in a concentration of 25mg/kg to the five mice groups once weekly for a period of 5weeks to induce a lupus-like condition. The untreated group was the normal control group. To confirm the development of lupus, an ANA test was conducted. After the mice tested positive for ANA, drug treatments commenced. The negative control group did not receive any drug treatment. The treatments included prednisolone, methotrexate and vitamin E, all administered at a concentration of 25mg/kg, with a higher dose of vitamin E (50mg/kg) also administered. Results Notably, on day 35, after drug treatment, we observed that mice that received vitamin E at a dosage of 50mg/kg (3.01±0.100) had a slight decrease in lymphocyte hydrogen peroxide radicals when compared with the group receiving 25mg/kg of vitamin E (3.30±0.100) (p<0.05). This finding suggests that the scavenging potential of vitamin E is dose dependent. Conclusion This study suggests that vitamin E supplementation, especially at a higher dose (50mg/ kg), holds promise in ameliorating lupus-like conditions. These findings warrant further exploration and may offer a potential avenue for improving the disease status of patients experiencing SLE.
Description
Article
Keywords
vivo ameliorative, vitamin E, hydralazine-induced lupus
Citation
Githaiga FM, Omwenga GI, Ngugi MP. In vivo ameliorative effects of vitamin E against hydralazine-induced lupus. Lupus Science & Medicine 2023;10:e001033. doi:10.1136/ lupus-2023-001033